Unbiased Cell Surface Proteomics Identifies SEMA4A as an Effective Immunotherapy Target for Myeloma

Using knock-down by shRNA and CRISPR/dCas9, scientists demonstrated that expression of SEMA4A was essential for normal myeloma cell growth in vitro, indicating that myeloma cells cannot downregulate the protein to avoid detection.